LAUREN WOODWARD: Open Payments
NPI 1942896808 · KING OF PRUSSIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,293 in 59 payments from 13 companies in 2025. Trend: 2023 $1,066 · 2024 $2,750 · 2025 $1,293
Food & beverage: $1,293
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $270 |
| CSL Behring | 8 | $208 |
| GlaxoSmithKline, LLC. | 9 | $187 |
| GENZYME CORPORATION | 8 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $120 |
| Genentech USA, Inc. | 4 | $102 |
| Azurity Pharmaceuticals, Inc. | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Grifols USA, LLC | 1 | $38 |
| Hikma Pharmaceuticals USA | 2 | $37 |
Products named: DUPIXENT, Hizentra, FASENRA, Xolair, CUVITRU, TEZSPIRE, TRELEGY ELLIPTA, NUCALA.
Industry payments across PA — which companies pay providers there.
